Research & Literature

Current challenges in the management of hemophilia.

Bauer KA

The American journal of managed care 2015; (21(6 Suppl)):S112-22.

Hemophilia in the managed care setting.

Dalton DR

The American journal of managed care 2015; (21(6 Suppl)):S123-30.

The current role of orthoses in treating haemophilic arthropathy.

De la Corte-Rodriguez H, Rodriguez-Merchan EC

Haemophilia : the official journal of the World Federation of Hemophilia 2015; (21(6)):723-30 doi:10.1111/hae.12779.

Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile.

Lillicrap D, Schiviz A, Apostol C, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2016; (22(2)):308-317 doi:10.1111/hae.12784.

Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study.

Antun A, Monahan PE, Manco-Johnson MJ, et al.

Journal of thrombosis and haemostasis : JTH 2015; (13(11)):1980-8 doi:10.1111/jth.13143.

Hemophilic arthropathy of the elbow: prophylaxis, imaging, and the role of invasive management.

Dale TM, Saucedo JM, Rodríguez-Merchán EC

Journal of shoulder and elbow surgery 2015; (24(10)):1669-78.

A milder clinical course for severe hemophilia B: a true or biased effect?

van Miert JH, Hop H, Borjas-Howard JF, Meijer K

Haematologica 2016; (101(6)):e266 doi:10.3324/haematol.2016.147298.

Evidence-based guidelines support integrated disease management as the optimal model of haemophilia care.

Pipe SW, Kessler CM

Haemophilia : the official journal of the World Federation of Hemophilia 2016; (22 Suppl 3()):3-5 doi:10.1111/hae.12997.

Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study.

Lane SJ, Sholapur NS, Yeung CH, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2016; (22 Suppl 3()):23-30 doi:10.1111/hae.13009.

Aspects of prophylactic treatment of hemophilia.

Ljung R

Thrombosis journal 2016; (14(Suppl 1)):30 doi:10.1186/s12959-016-0103-3.

Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study.

Witkop M, Neff A, Buckner TW, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2017; (23(4)):556-565 doi:10.1111/hae.13214.

Therapeutic plasma exchange as part of multimodal treatment of acquired hemophilia in a patient with concurrent acute intracerebral bleed and pulmonary embolism.

Wool GD, Chapel D, Treml A, Miller JL

Transfusion 2017; (57(7)):1827-1832 doi:10.1111/trf.14132.

Serological biomarkers detect active joint destruction and inflammation in patients with haemophilic arthropathy.

Hua B, Olsen EHN, Sun S, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2017; (23(4)):e294-e300 doi:10.1111/hae.13196.

Monitoring joint health in haemophilia: Factors associated with deterioration.

Kuijlaars IAR, Timmer MA, de Kleijn P, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2017; (23(6)):934-940 doi:10.1111/hae.13327.

Intracranial hemorrhage in congenital bleeding disorders.

Tabibian S, Motlagh H, Naderi M, Dorgalaleh A

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2018; (29(1)):1-11 doi:10.1097/MBC.0000000000000660.

Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.

Peyvandi F, Cannavò A, Garagiola I, et al.

Journal of thrombosis and haemostasis : JTH 2018; (16(1)):39-43 doi:10.1111/jth.13888.

Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?

Hazendonk HCAM, van Moort I, Mathôt RAA, et al.

Blood reviews 2018; (32(4)):265-271 doi:10.1016/j.blre.2018.01.001.

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.

Carcao M, Shapiro A, Staber JM, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2018; (24(2)):245-252 doi:10.1111/hae.13413.

Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003-2015: A national cohort study.

Chalmers EA, Alamelu J, Collins PW, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2018; (24(4)):641-647 doi:10.1111/hae.13461.

Extended Half-Life Factor VIII and Factor IX Preparations.

Graf L

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2018; (45(2)):86-91 doi:10.1159/000488060.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

Mahlangu J, Oldenburg J, Paz-Priel I, et al.

The New England journal of medicine 2018; (379(9)):811-822 doi:10.1056/NEJMoa1803550.

An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B.

Machin N, Ragni MV

Journal of blood medicine 2018; (9()):135-140 doi:10.2147/JBM.S159297.

Acute Life-Threatening Hemorrhage in Neonates With Severe Hemophilia A: A Report of 3 Cases.

Moreira A, Das H

Journal of investigative medicine high impact case reports 2018; (6()):2324709618800349 doi:10.1177/2324709618800349.

Emicizumab: Review of the literature and critical appraisal.

Rodriguez-Merchan EC, Valentino LA

Haemophilia : the official journal of the World Federation of Hemophilia 2019; (25(1)):11-20 doi:10.1111/hae.13641.

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.

Samelson-Jones BJ, Arruda VR

Molecular therapy. Methods & clinical development 2019; (12()):184-201 doi:10.1016/j.omtm.2018.12.007.

The role of orthopaedic surgery in haemophilia: current rationale, indications and results.

Rodríguez-Merchán EC

EFORT open reviews 2019; (4(5)):165-173 doi:10.1302/2058-5241.4.180090.

Mechanisms of vascular permeability and remodeling associated with hemarthrosis in factor VIII-deficient mice.

Cooke EJ, Wyseure T, Zhou JY, et al.

Journal of thrombosis and haemostasis : JTH 2019; (17(11)):1815-1826 doi:10.1111/jth.14567.

Effect of Prophylactic Management of Hemophilia on Bleeding Episodes.

Roy S, De AK

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2019; (35(3)):496-501 doi:10.1007/s12288-018-1054-6.

Merging into the mainstream: the evolution of the role of point-of-care musculoskeletal ultrasound in hemophilia.

Bakeer N, Shapiro AD

F1000Research 2019; (8()) doi:10.12688/f1000research.16039.1.

Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries.

Iorio A, Stonebraker JS, Chambost H, et al.

Annals of internal medicine 2019; (171(8)):540-546 doi:10.7326/M19-1208.

Clinical pattern of hemophilia and causes of variability.

Mingot-Castellano ME

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2019; (30(1S Suppl 1)):S4-S6 doi:10.1097/MBC.0000000000000821.

Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.

Ebbert PT, Xavier F, Seaman CD, Ragni MV

Haemophilia : the official journal of the World Federation of Hemophilia 2020; (26(1)):41-46 doi:10.1111/hae.13877.

Gene therapy for hemophilia.

Nathwani AC

Hematology. American Society of Hematology. Education Program 2019; (2019(1)):1-8 doi:10.1182/hematology.2019000007.

Hemophilia A in Females: Considerations for Clinical Management.

Bryant P, Boukouvala A, McDaniel J, Nance D

Acta haematologica 2020; (143(3)):289-294 doi:10.1159/000503889.

The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer.

Xiang Z, Kurupati RK, Li Y, et al.

Molecular therapy : the journal of the American Society of Gene Therapy 2020; (28(3)):771-783 doi:10.1016/j.ymthe.2019.11.014.

Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.

Carcao M, Zunino L, Young NL, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2020; (26(1)):73-78 doi:10.1111/hae.13905.

Effect of low-dose factor VIII prophylaxis therapy on bone mineral density and 25(OH) vitamin D level in children with severe haemophilia A.

Gamal Andrawes N, Hashem Fayek M, Salah El-Din N, Atef Mostafa R

Haemophilia : the official journal of the World Federation of Hemophilia 2020; (26(2)):325-332 doi:10.1111/hae.13917.

Molecular Mechanisms of Inhibitor Development in Hemophilia.

Tieu P, Chan A, Matino D

Mediterranean journal of hematology and infectious diseases 2020; (12(1)):e2020001 doi:10.4084/MJHID.2020.001.

Management of intracranial hemorrhage in hemophilia A patients.

Aras M, Oral S

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2020; (36(9)):2041-2046 doi:10.1007/s00381-020-04528-3.

Molecular characterization of hemophilia B patients in Colombia.

Parrado Jara YA, Yunis Hazbun LK, Linares A, Yunis Londoño JJ

Molecular genetics & genomic medicine 2020; (8(5)):e1210 doi:10.1002/mgg3.1210.

Left atrial appendage closure: a balanced management of the thromboembolic risk in patients with hemophilia and atrial fibrillation.

Toselli M, Bosi D, Benatti G, et al.

Journal of thrombosis and thrombolysis 2020; (50(3)):668-673 doi:10.1007/s11239-020-02097-5.

Six molecular patterns leading to hemophilia A phenotype in 18 females from Poland.

Janczar S, Babol-Pokora K, Jatczak-Pawlik I, et al.

Thrombosis research 2020; (193()):9-14 doi:10.1016/j.thromres.2020.05.041.

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B

Thrombosis and haemostasis 2020; (120(10)):1357-1370 doi:10.1055/s-0040-1714279.

Complications of hemophilia in the elbow: current management.

Rodriguez-Merchan EC, De la Corte-Rodriguez H

Expert review of hematology 2020; (13(9)):991-1001 doi:10.1080/17474086.2020.1803061.

Immunotolerance induction effectivity in hemophilia A children and neutralizing alloantibodies.

Soto A V, Cortez S D, González S M

Revista chilena de pediatria 2020; (91(2)):232-238 doi:10.32641/rchped.v91i2.1364.

European principles of inhibitor management in patients with haemophilia: implications of new treatment options.

Hermans C, Giangrande PLF, O'Mahony B, et al.

Orphanet journal of rare diseases 2020; (15(1)):219 doi:10.1186/s13023-020-01511-8.

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.

Konkle BA, Shapiro AD, Quon DV, et al.

The New England journal of medicine 2020; (383(11)):1018-1027 doi:10.1056/NEJMoa2002699.

Long-Term Antithrombotic Treatments Prescribed for Cardiovascular Diseases in Patients with Hemophilia: Results from the French Registry.

Guillet B, Cayla G, Lebreton A, et al.

Thrombosis and haemostasis 2021; (121(3)):287-296 doi:10.1055/s-0040-1718410.

Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities-a practical review.

Hermans C, Dolan G

Therapeutic advances in hematology 2020; (11()):2040620720966888 doi:10.1177/2040620720966888.

Factors Associated with Compliance with the Treatment Protocol and Mortality in Adults with Hemophilia.

Soares BMD, Simeoni LA, de Almeida KJQ, et al.

Patient preference and adherence 2020; (14()):2279-2285 doi:10.2147/PPA.S279401.

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.

Mancuso ME, Reding MT, Negrier C, et al.

Thrombosis and haemostasis 2021; (121(8)):1079-1086 doi:10.1055/a-1333-5536.

MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia.

Kwak H, Lee S, Jo S, et al.

Research and practice in thrombosis and haemostasis 2020; (4(8)):1301-1312 doi:10.1002/rth2.12438.

Genetic causes of haemophilia in women and girls.

Miller CH, Bean CJ

Haemophilia : the official journal of the World Federation of Hemophilia 2021; (27(2)):e164-e179 doi:10.1111/hae.14186.

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.

Pasi KJ, Lissitchkov T, Mamonov V, et al.

Journal of thrombosis and haemostasis : JTH 2021; (19(6)):1436-1446 doi:10.1111/jth.15270.

Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample.

Johnston K, Stoffman JM, Mickle AT, et al.

Patient preference and adherence 2021; (15()):1407-1417 doi:10.2147/PPA.S316276.

Hemophilic arthropathy: Current knowledge and future perspectives.

Gualtierotti R, Solimeno LP, Peyvandi F

Journal of thrombosis and haemostasis : JTH 2021; (19(9)):2112-2121 doi:10.1111/jth.15444.

Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.

Pasi KJ, Laffan M, Rangarajan S, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2021; (27(6)):947-956 doi:10.1111/hae.14391.

Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model.

Zhu J, Wu YS, Beechinor RJ, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2021; (27(6)):974-983 doi:10.1111/hae.14393.

Low immunogenicity of emicizumab in persons with haemophilia A.

Schmitt C, Emrich T, Chebon S, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2021; (27(6)):984-992 doi:10.1111/hae.14398.

[Treatment of haemophilia: From replacement to gene therapy].

Páramo JA

Medicina clinica 2021; (157(12)):583-587 doi:10.1016/j.medcli.2021.04.031.

All-cause mortality and causes of death in persons with haemophilia: A systematic review and meta-analysis.

Alam AU, Karkhaneh M, Attia T, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2021; (27(6)):897-910 doi:10.1111/hae.14423.

Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success.

Elalfy M, Elghamry I, Hassab H, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2022; (28(1)):65-72 doi:10.1111/hae.14456.

Left atrial appendage occlusion in haemophilia patients with atrial fibrillation.

Kramer AD, Korsholm K, Kristensen A, et al.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2022; (64(1)):95-102 doi:10.1007/s10840-021-01090-z.

The Clinical Genetics of Hemophilia B (Factor IX Deficiency).

Miller CH

The application of clinical genetics 2021; (14()):445-454 doi:10.2147/TACG.S288256.

Multidisciplinary Team Care of Patients with Hemophilic Arthropathy: A Qualitative Assessment of Contemporary Practice in the UK and Canada : Canada/UK: MDT Practices for Hemophilia.

St-Louis J, Chowdary P, Dolan G, et al.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2022; (28()):10760296211070002 doi:10.1177/10760296211070002.

Medical costs and hospital utilization for hemophilia A and B urban inpatients in China: a national cross-sectional study.

Huang Z, Nicholas S, Yang Y, et al.

BMC health services research 2022; (22(1)):230 doi:10.1186/s12913-022-07626-x.

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.

Ozelo MC, Mahlangu J, Pasi KJ, et al.

The New England journal of medicine 2022; (386(11)):1013-1025 doi:10.1056/NEJMoa2113708.

Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis.

Citla-Sridhar D, Sidonio RF, Ahuja SP

Haemophilia : the official journal of the World Federation of Hemophilia 2022; (28(4)):671-678 doi:10.1111/hae.14565.

Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues.

Weyand AC, Sidonio RF, Sholzberg M

Haemophilia : the official journal of the World Federation of Hemophilia 2022; (28 Suppl 4()):18-25 doi:10.1111/hae.14535.

The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHESS II Study.

Ferri Grazzi E, Sun SX, Burke T, O'Hara J

Journal of blood medicine 2022; (13()):505-516 doi:10.2147/JBM.S363028.

From a bispecific monoclonal antibody to gene therapy: A new era in the treatment of hemophilia A.

Mihaila RG

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2023; (167(1)):1-8 doi:10.5507/bp.2022.046.

Gene therapy for hemophilia: looking beyond factor expression.

Yamaguti-Hayakawa GG, Ozelo MC

Experimental biology and medicine (Maywood, N.J.) 2022; (247(24)):2223-2232 doi:10.1177/15353702221147565.

Molecular pathogenesis of a novel Met394Thr variant causing hemophilia B.

Lu L, Wang L, Shen W, et al.

Molecular genetics & genomic medicine 2023; (11(5)):e2147 doi:10.1002/mgg3.2147.

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.

Pipe SW, Leebeek FWG, Recht M, et al.

The New England journal of medicine 2023; (388(8)):706-718 doi:10.1056/NEJMoa2211644.

Hemophilia A: Emicizumab monitoring and impact on coagulation testing.

Nardi MA

Advances in clinical chemistry 2023; (113()):273-315 doi:10.1016/bs.acc.2022.12.001.

Acute coronary syndrome management in hemophiliacs: How to maintain balance?: A review.

Chen H, Yang S

Medicine 2023; (102(11)):e33298 doi:10.1097/MD.0000000000033298.

Ferroptosis: a new target for iron overload-induced hemophilic arthropathy synovitis.

Han Z, Zheng L, Luo D, et al.

Annals of hematology 2023; (102(5)):1229-1237 doi:10.1007/s00277-023-05190-w.

The hidden joint in children with haemophilia on prophylaxis.

Daffunchio C, Galatro G, Faurlin V, et al.

Thrombosis research 2023; (226()):86-92 doi:10.1016/j.thromres.2023.04.012.

Practices and challenges for hemophilia management under resource constraints in Thailand.

Moonla C, Sosothikul D, Pongtanakul B, et al.

Orphanet journal of rare diseases 2023; (18(1)):110 doi:10.1186/s13023-023-02718-1.

Etranacogene dezaparvovec for hemophilia B gene therapy.

Thornburg CD

Therapeutic advances in rare disease 2021; (2()):26330040211058896 doi:10.1177/26330040211058896.

Hemophilia Joint Health Score, Functional Independence Score in Hemophilia, and Pettersson Score in Pediatric Patients With Severe Hemophilia A.

Mabrouk AG, Abbas MAE, Ezzat DA, et al.

Journal of pediatric hematology/oncology 2023; (45(6)):344-348 doi:10.1097/MPH.0000000000002692.

Clotting Factor Deficiencies as an Underlying Cause of Abnormal Uterine Bleeding in Women of Reproductive Age: A Literature Review.

Livanou ME, Matsas A, Valsami S, et al.

Life (Basel, Switzerland) 2023; (13(6)) doi:10.3390/life13061321.

Hemophilic arthropathy: how to diagnose subclinical bleeding early and how to orthopedically treat a damaged joint.

Rodriguez-Merchan EC

Expert review of hematology 2023; (16(9)):651-658 doi:10.1080/17474086.2023.2232547.

Clinicopathological Parameters of Haemophilia Patients at a Tertiary Care Centre in Northern India.

Singh A, Rawat S, Kushwaha R, et al.

Cureus 2023; (15(7)):e41670 doi:10.7759/cureus.41670.

Gene therapy vector-related myocarditis.

Silver E, Argiro A, Hong K, Adler E

International journal of cardiology 2024; (398()):131617 doi:10.1016/j.ijcard.2023.131617.

Current limitations of gene therapy for rare pediatric diseases: Lessons learned from clinical experience with AAV vectors.

Gardin A, Ronzitti G

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2023; (30(8S1)):8S46-8S52 doi:10.1016/S0929-693X(23)00227-0.

Blood-Induced Arthropathy: A Major Disabling Complication of Haemophilia.

Leuci A, Dargaud Y

Journal of clinical medicine 2023; (13(1)) doi:10.3390/jcm13010225.

Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A.

Abdelgawad HAH, Foster R, Otto M

Blood reviews 2024; (64()):101164 doi:10.1016/j.blre.2023.101164.

Fidanacogene Elaparvovec: First Approval.

Dhillon S

Drugs 2024; (84(4)):479-486 doi:10.1007/s40265-024-02017-4.

Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.

Srichumpuang C, Rakmanotham A, Moonla C, Sosothikul D

Orphanet journal of rare diseases 2024; (19(1)):135 doi:10.1186/s13023-024-03092-2.

Women and girls with inherited bleeding disorders: Focus on haemophilia carriers and heavy menstrual bleeding.

Hermans C, Johnsen JM, Curry N

Haemophilia : the official journal of the World Federation of Hemophilia 2024; (30 Suppl 3()):45-51 doi:10.1111/hae.14983.

The good, the bad and the ugly of pain in haemophilia: Recent evidence on the epidemiology, molecular mechanisms and knowledge gaps preventing optimal treatment.

Benemei S, Mattia C, Di Minno MND

Haemophilia : the official journal of the World Federation of Hemophilia 2024; (30(3)):589-597 doi:10.1111/hae.15002.

Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives.

Bala NS, Thornburg CD

Seminars in thrombosis and hemostasis 2025; (51(1)):28-40 doi:10.1055/s-0044-1785483.

Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.

Oldenburg J, Chambost H, Liu H, et al.

Advances in therapy 2024; (41(6)):2267-2281 doi:10.1007/s12325-024-02834-9.

Roctavian gene therapy for hemophilia A.

Samelson-Jones BJ, Small JC, George LA

Blood advances 2024; (8(19)):5179-5189 doi:10.1182/bloodadvances.2023011847.

Acute Abdominal Crisis in Type A Hemophilia: Unraveling Retroperitoneal Hematoma: A Case Report.

Althobaiti HA, Alabou Houseen BF, Alsaqqa EM, et al.

The American journal of case reports 2024; (25()):e944694 doi:10.12659/AJCR.944694.

Hemophilia and Other Congenital Coagulopathies in Women.

Green D

Journal of hematology 2024; (13(4)):137-141 doi:10.14740/jh1298.

Prevalence of Hemophilia and Clinicodemographic Characteristics of Hemophilic Patients Aged ≤ 18 Years in Thi-Qar, Iraq.

Abood GM, Dehiol RK, Mones HM

Global pediatric health 2024; (11()):2333794X241280119 doi:10.1177/2333794X241280119.

Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.

Cuker A, Kavakli K, Frenzel L, et al.

The New England journal of medicine 2024; (391(12)):1108-1118 doi:10.1056/NEJMoa2302982.

MR Imaging of Hemosiderin Deposition in the Ankle Joints of Patients with Haemophilia: The Contribution of a Multi-Echo Gradient-Echo Sequence-Correlation with Osteochondral Changes and the Number and Chronicity of Joint Bleeds.

Papakonstantinou O, Karavasilis E, Martzoukos E, et al.

Life (Basel, Switzerland) 2024; (14(9)) doi:10.3390/life14091112.

Comparing one stage, chromogenic assay results and discrepancies with bleeding phenotype and genetic variants in females with hemophilia A.

Srivaths L, Larson J, Saroukhani S, et al.

Journal of thrombosis and haemostasis : JTH 2025; (23(2)):504-512 doi:10.1016/j.jtha.2024.10.030.

Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document.

Escobar M, Lassila R, Bekdache C, et al.

Journal of thrombosis and haemostasis : JTH 2025; (23(2)):745-749 doi:10.1016/j.jtha.2024.10.033.

Effect of Blood on Synovial Joint Tissues: Potential Role of Ferroptosis.

Nicholson HJ, Sakhrani N, Rogot J, et al.

Applied sciences (Basel, Switzerland) 2024; (14(14)) doi:10.3390/app14146292.

The influence of severity of hemophilia on bone mineral density and fracture risk.

Ransmann P, Hmida J, Brühl M, et al.

Research and practice in thrombosis and haemostasis 2024; (8(8)):102624 doi:10.1016/j.rpth.2024.102624.

Epilepsy and Other Neurological Complications in Pediatric Patients With Hemophilia Complicated With Intracranial Hemorrhage: A Retrospective Case Series.

Eguchi Y, Ishikawa N, Kobayashi Y, et al.

Cureus 2024; (16(11)):e74261 doi:10.7759/cureus.74261.

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Choví-Trull M, Megías-Vericat JE, Bonanad Boix S, et al.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2025; (49(4)):T205-T211 doi:10.1016/j.farma.2024.12.007.

Haemophilia.

Chowdary P, Carcao M, Kenet G, Pipe SW

Lancet (London, England) 2025; (405(10480)):736-750 doi:10.1016/S0140-6736(24)02139-1.

Bone Health Screening in Persons With Bleeding Disorders: A Survey of United States Haemophilia Treatment Centres.

Citla-Sridhar D, Ahuja S, Sidonio R, et al.

Haemophilia : the official journal of the World Federation of Hemophilia 2025; (31(3)):519-525 doi:10.1111/hae.70027.

Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance.

Konkle BA, Peyvandi F, Foster GR, et al.

Journal of thrombosis and haemostasis : JTH 2025; (23(7)):2086-2094 doi:10.1016/j.jtha.2025.02.042.

Adeno-associated virus gene therapy for hemophilia: an update meta-analysis and systematic review.

Yang W, Wang A, Liu B

Frontiers in medicine 2025; (12()):1580264 doi:10.3389/fmed.2025.1580264.

Missense and nonsense mutations and inhibitor development in patients with hemophilia A and B.

Karimi F, Saki N, Khademi R, et al.

Journal of thrombosis and thrombolysis 2026; (59(1)):210-219 doi:10.1007/s11239-025-03171-6.

Journeying Towards Excellence in the Care of Patients with Haemophilia and Other Inherited Bleeding Disorders From a Developing World: Insights From Tanzania.

Rwezaula SS, Mtoba SD, Gosse RA, et al.

Journal of blood medicine 2025; (16()):413-423 doi:10.2147/JBM.S537383.

Updated Egyptian national guidelines for management of hemophilia A in children & adolescents.

Mokhtar G, El-Beshlawy A, Alfy ME, et al.

Annals of hematology 2025; (104(10)):5463-5473 doi:10.1007/s00277-025-06557-x.

Quantifying the optimal factor VIII levels to achieve patient-centric and clinician-relevant outcomes among people with hemophilia A: a SHELF elicitation study.

Burke T, Blenkiron T, Mancuso ME, et al.

Expert review of hematology 2026; (19(1)):55-61 doi:10.1080/17474086.2025.2574715.

Guilt in parents of children diagnosed with hemophilia: A qualitative study.

Onel AE, Zengin D, Bal Yilmaz H

Journal of pediatric nursing 2026; (86()):51-59 doi:10.1016/j.pedn.2025.10.032.

Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors.

Alashqar MT, Nahata MC

The Annals of pharmacotherapy 2026; (60(7)):700-709 doi:10.1177/10600280251403512.

Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B.

Rehman RU, Fatima R, Akilimali A

Health science reports 2026; (9(1)):e71702 doi:10.1002/hsr2.71702.

Frequency of T Regulatory Cells Subpopulations in Hemophilia A Patients with Inhibitors.

Arreola-Díaz R, Hernández-Juárez J, Ricardo-Moreno T, et al.

Hamostaseologie 2026; doi:10.1055/a-2698-0263.